Infliximab maintenance therapy for fistulizing Crohn's disease.
- B. Sands, F. Anderson, S. V. van Deventer
- MedicineNew England Journal of Medicine
- 26 February 2004
Patients with fistulizing Crohn's disease who have a response to induction therapy with inflIXimab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks.
Infliximab for the treatment of fistulas in patients with Crohn's disease.
- D. Present, P. Rutgeerts, S. V. van Deventer
- MedicineNew England Journal of Medicine
- 6 May 1999
Infliximab is an efficacious treatment for fistulas in patients with Crohn's disease and the most common adverse events for patients treated with infliximab were headache, abscess, upper respiratory tract infection, and fatigue.
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
- S. Targan, S. Hanauer, P. Rutgeerts
- MedicineNew England Journal of Medicine
- 1997
A single infusion of cA2 was an effective short-term treatment in many patients with moderate-to-severe, treatment-resistant Crohn's disease.
Natalizumab induction and maintenance therapy for Crohn's disease.
- W. Sandborn, J. Colombel, P. Rutgeerts
- MedicineNew England Journal of Medicine
- 3 November 2005
Induction therapy with natalizumab for Crohn's disease resulted in small, nonsignificant improvements in response and remission rates, which will need to be weighed against the risk of serious adverse events.
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
- P. Rutgeerts, G. D'Haens, S. V. van Deventer
- MedicineGastroenterology
- 1 October 1999
Cloning and characterization of cDNAs for murine macrophage inflammatory protein 2 and its human homologues
- P. Tekamp-Olson, C. Gallegos, A. Cerami
- Biology, ChemistryJournal of Experimental Medicine
- 1 September 1990
A cDNA clone of murine macrophage inflammatory protein 2 (MIP-2) has been isolated from a library prepared from lipopolysaccharide (LPS)- stimulated RAW 264.7 cells and the nucleotide sequence…
Leptin is a growth factor for colonic epithelial cells.
- J. C. Hardwick, G. R. van den Brink, G. Offerhaus, S. V. van Deventer, M. P. Peppelenbosch
- Biology, MedicineGastroenterology
- 1 July 2001
Leptin is a growth factor in colonic epithelial cells and one that may provide a biological explanation for the observed associations between obesity, physical activity, and colon cancer.
Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets
- D. Hommes, M. Peppelenbosch, S. V. van Deventer
- Biology, ChemistryGut
- 1 January 2003
Current understanding of the MAP kinase pathway is reviewed, as well as recent advances in the design of novel agents that are able to modulate the activity of these signalling cascades.
Distribution and Kinetics of Lipoprotein-Bound Endotoxin
- J. Levels, P. Abraham, A. E. van den Ende, S. V. van Deventer
- Biology, MedicineInfection and Immunity
- 1 May 2001
Under simulated physiological conditions, the binding of LPS to lipoproteins is highly specific, HDL has the highest binding capacity for LPS, the saturation capacity of lipoproduins for endotoxin far exceeds the LPS concentrations measured in clinical situations, and the kinetics of L PS association with lipoprotein display chemotype-dependent differences.
...
...